Understanding Schizophrenia: Symptoms, Causes, and Treatment Options
Introduction
Schizophrenia is a complex mental health condition characterized by a wide range of symptoms that significantly impair daily functioning and overall well-being. In this comprehensive guide, we will explore, in detail, the various causes, symptoms, and treatment options associated with schizophrenia. Specifically, we will focus on the neurochemical imbalances—such as those involving dopamine, glutamate, serotonin, and GABA—that play a crucial role in the development and progression of this disorder. By understanding these factors, we can gain deeper insights into how schizophrenia affects individuals and, as a result, how it can be more effectively managed.
What Is Schizophrenia?
Schizophrenia is a severe psychiatric disorder that is characterized by a mix of symptoms, which are typically categorized into three primary types: positive (psychotic), negative, and cognitive. Understanding these symptom categories is crucial for both diagnosis and treatment, as it enables clinicians to tailor interventions to manage the disorder more effectively.
Symptoms of Schizophrenia
1. Positive Symptoms (Psychotic Symptoms)
Positive symptoms reflect an overactivity or distortion of normal cognitive functions. Specifically, these include:
- Hallucinations: Perceptions without external stimuli. For example, these can include auditory, visual, or tactile experiences:
- Auditory (e.g., hearing voices)
- Visual (e.g., seeing things that aren’t there)
- Tactile (e.g., feeling sensations that are not real)
- Olfactory (e.g., smelling odors that others cannot)
- Gustatory (e.g., tasting things that aren’t there)
- Delusions: Strongly held false beliefs, such as feeling persecuted or believing one has special powers.
- Disorganized Thinking: This includes, for example, incoherent speech and difficulty maintaining logical connections in thought.
- Movement Disorders: Abnormal motor behavior, such as agitation or catatonia (lack of movement or response).
2. Negative Symptoms
These symptoms reflect a reduction or loss of normal functions, including:
- Affective Flattening: Limited emotional expression, such as a lack of facial expressions or voice tone variation.
- Anhedonia: Inability to experience pleasure or interest in once enjoyable activities.
- Alogia: Specifically, reduced speech output, often manifesting as brief, empty responses.
- Avolition: In addition, a lack of motivation to start and complete purposeful tasks.
- Asociality: Furthermore, withdrawal from social interactions and relationships.
3. Cognitive Symptoms
These impairments significantly impact essential mental functions, including:
- Impaired Executive Functioning: This involves difficulty in planning, organizing, and making decisions, which in turn affects both daily tasks and long-term goals.
- Attention Deficits: Individuals may struggle to maintain focus, which, as a result, often leads to distractions and challenges in completing tasks.
- Memory Problems: Additionally, there can be difficulty with working memory, making it harder to retain and use information immediately after learning.
Cognitive difficulties often overlap with other symptoms, further complicating day-to-day functioning and mental performance.
Causes and Pathophysiology of Schizophrenia
Schizophrenia’s origins are linked to neurochemical imbalances, particularly involving dopamine, glutamate, serotonin, and GABA. Key hypotheses include:
- Dopamine Hypothesis: Overactive dopamine activity in the mesolimbic pathway contributes to positive symptoms, while reduced dopamine in the prefrontal cortex is linked to negative symptoms.
- Glutamate Hypothesis: Reduced glutamate activity and NMDA receptor dysfunction can therefore mimic schizophrenia-like symptoms. Imbalances in GABA neurotransmission may also play a role.
- Serotonin’s Role: Fluctuations in serotonin levels influence dopamine regulation, affecting both positive and negative symptoms.
Diagnosis of Schizophrenia
Schizophrenia is diagnosed based on the presence of certain criteria, which include:
- Delusions
- Hallucinations
- Disorganized speech
- Catatonic or grossly disorganized behavior
- Negative symptoms (e.g., diminished emotional expression or avolition)
Managing Schizophrenia: Treatment Phases
Schizophrenia treatment is typically divided into three key phases:
Acute Phase:
- Symptoms: Severe psychotic symptoms, such as delusions and hallucinations.
- Goals: The primary objectives are, first and foremost, to achieve rapid symptom reduction; subsequently, to ensure patient safety; and ultimately, to manage severe agitation effectively.
Treatment: To achieve these goals, the treatment plan typically involves the initiation of antipsychotic medications, coupled with supportive care. In some cases, hospitalization may also be necessary to provide a safe and controlled environment for the patient during the acute phase.
Stabilization Phase:
- Symptoms: Reduction of acute symptoms but still at risk of relapse.
- Goals: Therefore, The goals are to maintain treatment effectiveness, address lingering symptoms, and prepare for long-term management.
- Treatment: In terms of treatment, this entails continued antipsychotic therapy, along with regular symptom monitoring and proactive long-term management planning.
Stable Phase:
Symptoms: The focus is on chronic symptom management.
Goals: Therefore, the primary objectives are to prevent relapse and maintain long-term stability.
Treatment: This includes ongoing medication, continued community support, and access to rehabilitation services.
Understanding Antipsychotic Medications: Neurotransmitter Pathways and Their Effects
Neurotransmitter Pathway | Function | Typical Antipsychotics | Atypical Antipsychotics |
Dopamine-nigrostriatal | Modulates Extrapyramidal Symptoms (EPS) | Potent D2 receptor blockade; often leads to EPS | As a result, there is minimal EPS due to the selective action on the mesolimbic pathway |
Dopamine-mesolimbic | Arousal, Memory, Behavior | Effective for managing positive symptoms | Effective for managing positive symptoms and reducing agitation |
Dopamine-mesocortical | Cognition, Socialization, Negative Symptoms | Less effective for negative symptoms | Clozapine and other SGAs are more effective for negative symptoms; and may offer cognitive improvements |
Dopamine-tuberoinfundibular | Prolactin Release | Increases prolactin levels; dose-dependent | No significant increase in prolactin with Clozapine; minimal with other SGAs |
Serotonergic (5-HT2) | Reduces EPS, Improves Negative Symptoms | Minimal 5-HT2 receptor affinity | Higher 5-HT2 receptor affinity; better for reducing EPS and improving negative symptoms |
Explanation of Key Terms:
- Extrapyramidal Symptoms (EPS): Movement disorders such as tremors or rigidity caused by antipsychotic medications, particularly those with strong D2 receptor blockade.
- D2 Receptor Blockade: Interaction with dopamine D2 receptors which can lead to motor side effects.
- 5-HT2 Receptor Affinity: Binding to serotonin 5-HT2 receptors, impacting the effectiveness of medications in reducing EPS and managing negative symptoms.
Why This Information Matters:
- Motor Control and EPS: Understanding how different antipsychotic medications affect motor control is essential, since it helps, in turn, to select treatments that minimize side effects.
- Effectiveness in Symptom Management: By comparing typical vs. atypical antipsychotics, we can gain valuable insight into their efficacy in treating both positive and negative symptoms of schizophrenia.
- Prolactin Effects: Moreover, managing prolactin levels is crucial for reducing side effects associated with antipsychotic treatments.
- Serotonin Receptor Interactions: In addition, knowledge of serotonin receptor interactions plays a key role in choosing medications that effectively balance both treatment efficacy and side effects.
New Drug Approval -2024 in Psychiatry – FDA –
- COBENFY (Xanomeline {a Muscarinic Agonist} + Trospium chloride {Muscarinic Antagonist}).
Mechanism of action (MOA) of COBENFY:
How Xanomeline works to treat schizophrenia isn’t fully understood. However, it’s believed to help by activating M1 and M4 receptors in the brain. Trospium chloride, on the other hand, blocks muscarinic receptors, mainly outside the brain.
2. LYBALVI – Approved on May 28, 2021
LYBALVI is a medication that combines Olanzapine (an antipsychotic) and Samidorphan (an opioid blocker). It is approved for:
- Schizophrenia in adults.
- Bipolar I disorder, for treating manic or mixed episodes, either on its own or with other medications like lithium or valproate.
How it Works:
- Olanzapine helps control symptoms like hearing voices and mood swings, while Samidorphan reduces the weight gain caused by olanzapine.
Clinical Trials:
- Trial 1: Tested LYBALVI in patients with schizophrenia, showing it worked better than a placebo in reducing symptoms.
- Trial 2: Focused on weight management, showing LYBALVI caused less weight gain compared to olanzapine alone.
Side Effects:
- Serious risks: Specifically, these include stroke in older adults with dementia, opioid withdrawal, and muscle issues.
Common side effects: Additionally, patients may experience weight gain, sleepiness, dry mouth, headache, and dizziness.
Important Note: LYBALVI should not be used in older patients with dementia due to serious risks.
For more information, visit the FDA’s page on LYBALVI.
Guide to Antipsychotic Medications: Dosages, Safety, and Interactions
Medication | Potency | Primary Uses | Dosage Range | Forms | Safety Considerations | Interactions & Management |
Chlorpromazine | Low | Schizophrenia, Bipolar Disorder | Oral: 100-800 mg/day; IM: 400 mg/day | Tablets, Liquid, IM Injection | Risks: Sedation, EPS, cardiovascular issues. Management: Regular monitoring, and dose adjustments. | Interactions: Avoid sedatives. Special Notes: Adjust dosage for the elderly. APA Guidelines, 2023 |
Thioridazine | Low | Schizophrenia | Oral: 100-400 mg/day | Tablets | Cautions: Risk of QT prolongation. Management: Monitor ECG and electrolytes. | Interactions: Avoid QT-prolonging drugs. Special Notes: Caution in liver impairment. NICE Guidelines, 2023 |
Loxapine | Mild | Schizophrenia | Oral: 20-80 mg/day | Tablets, Capsules, Liquid | Risks: Sedation, EPS; hepatic issues. Management: Monitor liver function. | Interactions: Watch for liver effects with other drugs. Special Notes: Adjust for hepatic impairment. Cochrane Review, 2024 |
Perphenazine | Mild | Schizophrenia | Oral: 12-48 mg/day | Tablets | Risks: EPS, sedation. Management: Regular dose adjustments and monitoring. | Interactions: Be cautious with EPS-inducing drugs. Special Notes: Adjust for the elderly. JAMA Psychiatry, 2024 |
Fluphenazine | High | Schizophrenia | Oral: 5-20 mg/day; IM: 100 mg every 4-6 weeks | Tablets, IM Injection | Cautions: Monitor EPS and cardiovascular health. Management: Regular cardiovascular monitoring. | Interactions: Monitor blood pressure with antihypertensives. Special Notes: Adjust for the elderly. APA Guidelines, 2023 |
Trifluoperazine | High | Schizophrenia | Oral: 5-15 mg/day | Tablets, Liquid | Cautions: Monitor EPS and sedation. Management: Regular assessments and dose adjustments. | Interactions: Be cautious with CNS depressants. Special Notes: Adjust for age. NICE Guidelines, 2023 |
Flupenthixol | High | Schizophrenia | Oral: 3-15 mg/day; Depot: 20-60 mg every 2-4 weeks | Tablets, Depot Injections | Risks: EPS, cardiovascular issues. Management: Regular monitoring and cardiovascular assessments. | Interactions: Watch for hypotension with antihypertensives. Special Notes: Adjust for age. Cochrane Review, 2024 |
Zuclopenthixol | High | Schizophrenia | Oral: 20-40 mg/day; IM: 400 mg every 2 weeks | Tablets, IM Injection | Cautions: Monitor sedation and hypotension. Management: Gradual tapering, vital sign monitoring. | Interactions: Avoid abrupt discontinuation. Special Notes: Adjust dosage for the elderly. JAMA Psychiatry, 2024 |
Pimozide | High | Tourette Syndrome, Schizophrenia | Oral: 4-8 mg/day | Tablets | Cautions: Risk of QT prolongation. Management: Regular ECGs and liver function tests. | Interactions: Avoid QT-prolonging drugs. Special Notes: Adjust for hepatic impairment. APA Guidelines, 2023 |
Understanding Extrapyramidal Side Effects (EPS) and Neuroleptic Malignant Syndrome (NMS)
Extrapyramidal Side Effects (EPS)
Type of EPS | Symptoms | Onset | Treatment Options |
Acute Dystonia | Muscle spasms, laryngeal dystonia, oculogyric crisis, opisthotonos, trismus, torticollis | 1st hour to days after starting or increasing the dose | Anticholinergics (Diphenhydramine, Benztropine) |
Parkinsonism | Postural instability, akathisia/bradykinesia, rigidity, resting tremors | Typically within 4 weeks of starting or increasing the dose. | Anticholinergics (Trihexyphenidyl, Diphenhydramine, Benztropine), Propranolol |
Akathisia | Restlessness, urge to move, pacing, rocking | Varies | Anticholinergics, Benzodiazepines, Propranolol |
Tardive Dyskinesia (TD) | Involuntary movements affecting face, tongue, lips, neck, trunk, limbs | Long-term use | Discontinue drug, switch to SGAs (Clozapine, Quetiapine) |
- Seizures: In particular, these are more likely with Phenothiazines and Butyrophenones.
Cardiovascular Issues: Additionally, QT prolongation (as seen with Thioridazine), tachycardia, and orthostatic hypotension are also potential concerns.
- Elderly Risk: Antipsychotic drugs can increase mortality in elderly with dementia-related psychosis due to stroke and infection risks.
Neuroleptic Malignant Syndrome (NMS)
Symptom | Description | Treatment |
High Fever | Elevated body temperature | Cooling measures, antipyretics |
Severe Muscle Stiffness | “Lead pipe” rigidity | Muscle relaxants (benzodiazepines, dantrolene) |
Altered Mental Status | Confusion, agitation | Supportive care |
Additional Symptoms | Tachycardia, tachypnea, fluctuating blood pressure | Respiratory, cardiovascular, and circulatory support |
- Elevated Creatine Phosphokinase (CPK): This indicates muscle damage.
- Increased White Blood Cells (WBC): Similarly, this suggests inflammation or stress.
Neuroleptic Malignant Syndrome (NMS) Management
- Discontinue antipsychotics: This requires the immediate cessation of the offending drug.
- Supportive Care: Manage body temperature, electrolyte balance, and overall support.
- Cooling Measures: Use cooling beds, antipyretic medications, and cooled IV fluids.
- Muscle Relaxation: Administer dantrolene or benzodiazepines; bromocriptine may be used if necessary.
Comparative Overview of Adverse Effects of First-Generation Antipsychotics (FGAs)
Drug | Sedation | EPS (Extrapyramidal Symptoms) | Anticholinergic Effects | Orthostasis | Seizures | Prolactin Elevation | Weight Gain |
Chlorpromazine | ↑↑↑↑ | ↑↑↑ | ↑↑↑ | ↑↑↑↑ | ↑↑↑ | ↑↑↑ | ↑ |
Thioridazine | ↑↑↑↑ | ↑↑ | ↑↑↑↑ | ↑↑↑↑ | ↑↑ | ↑↑↑ | ↑↑ |
Haloperidol | ↓ | ↑↑↑↑↑ | ↓ | ↓ | ↑ | ↑↑ | ↑ |
Fluphenazine | ↑↑ | ↑↑↑↑↑ | ↑↑ | ↑↑ | ↑ | ↑↑ | ↑ |
Thiothixene | ↑↑ | ↑↑↑↑ | ↑↑ | ↑↑ | ↑ | ↑↑ | ↑ |
Trifluoperazine | ↑ | ↑↑↑↑ | ↑↑ | ↑↑ | ↑ | ↑↑ | ↑ |
Side effects of First generation Antipsychotics
- Sedation: This indicates the level of drowsiness or sleepiness induced by the drug.
- EPS: In addition, extrapyramidal symptoms include movement disorders such as tremors, rigidity, and bradykinesia.
- Anticholinergic Effects: These side effects may include dry mouth, blurred vision, and constipation..
- Orthostasis: Specifically, there is a risk of a sudden drop in blood pressure upon standing.
- Seizures: Moreover, there is a potential risk of seizures as a side effect of the drug.
- Prolactin Elevation: Furthermore, an increase in prolactin levels can occur, which may, in turn, affect reproductive and metabolic functions.
- Weight Gain: Additionally, there is a potential for weight gain associated with the medication, which should be considered in treatment planning.
1. Clozapine
Posology:
- Initial Dose: Oral Tablets or Suspension – 12.5 mg to 25 mg once or twice daily.
- Usual Dose: Oral Tablets or Suspension – 300 mg to 450 mg daily, divided into 2 or 3 doses.
- Maximum Dose: Oral Tablets or Suspension – 900 mg daily.
- Administration: Typically divided into 2 or 3 doses per day.
- Safety Notes: -CLOZAPINE(mnemonic):
- Cardiovascular issues (e.g., myocarditis), Leukopenia and agranulocytosis, Orthostatic hypotension, Sedation, Anticholinergic effects, Pulmonary embolism risk, Increased appetite, Nausea, Epileptic seizures.
2. Risperidone
Posology:
Oral Risperidone:
- Initial Dose: 1 mg daily.
- Subsequently, the Usual Dose: is 2-4 mg daily.
- However, the Maximum Dose: is 8 mg daily.
- For optimal results, Administration: 1-2 times daily
Injectable Risperidone:
- Initial Dose: Initially, 25 mg intramuscularly every 2 weeks (Risperdal Consta).
- Usual Dose: Typically, 25-50 mg intramuscularly every 2 weeks.
- Maximum Dose: The maximum recommended dose is 50 mg every 2 weeks.
- Monthly Formulation: 90 mg or 120 mg subcutaneously once a month (Risperdal Perseris).
Safety Notes: -RISPERS(mnemonic):
- Restlessness, Increased prolactin, Sedation, Parkinsonism, Extrapyramidal symptoms, Rapid weight gain, and Sexual dysfunction.
3. Olanzapine
Posology:
Oral Olanzapine:
- Initial Dose: 5-10 mg once daily.
- Usual Dose: 10-20 mg once daily.
- Maximum Dose: 30 mg once daily.
Injectable Olanzapine:
- Short-acting: 10-20 mg intramuscularly, administered every 2 to 4 weeks.
- Long-acting: 150-300 mg intramuscularly, administered every 2 to 4 weeks.
Safety Notes:
It is important to be aware of the potential side effects associated with Olanzapine, such as:- OLANZAPINE (Mnemonic):
- Obesity
- Lethargy
- Anticholinergic effects
- Nausea
- Sleep disturbances
- Metabolic syndrome
- Prolonged QT interval
4. Quetiapine
Posology:
Immediate-Release:
- Initial Dose: 50 mg twice daily.
- Usual Dose: Typically, 300–400 mg daily, divided into 2-3 doses.
- Maximum Dose: However, the maximum recommended dose is 800 mg daily
Extended-Release:
- Initial Dose: 300 mg once daily.
- Usual Dose: 400–800 mg once daily.
- Maximum Dose: 800 mg daily.
Safety Notes:
- SEDATION: Sedation, Eye issues (e.g., cataracts), Dizziness, Appetite increase, Tachycardia, Increased blood sugar, Oral health issues, Nausea.
5. Aripiprazole
Posology:
Oral Tablets:
- Initial Dose: 10–15 mg once daily.
- Usual Dose: 15–30 mg once daily.
- Maximum Dose: 30 mg once daily.
Intramuscular Injection:
- Initial Dose: 9.75 mg once every 4 weeks.
- Usual Dose: 9.75 mg to 19.5 mg every 4 weeks.
- Maximum Dose: 19.5 mg every 4 weeks.
Safety Notes: -ACTOR(mnemonic)
- Agitation, Constipation, Tremors, Oversleeping, Rash.
6. Paliperidone
Posology:
Oral Tablet (Extended Release):
- Initial Dose: 6 mg once daily.
- Usual Dose: 6-12 mg once daily.
- Maximum Dose: 12 mg once daily.
Injectable:
- 1-Month Formulation: 234 mg on Day 1 and 156 mg on Day 8, then 117 mg every 4 weeks.
- 3-Month Formulation: 819 mg on Day 1 and Day 8, then 273 mg every 3 months.
- Twice Yearly Formulation (Invega Hafyera): FDA Approval in 2021
Safety Notes: PILL-BOX (mnemonic)
- Prolactin increase, Increased weight, Leukopenia, Lethargy, Blurred vision, Orthostatic hypotension, Extra movement.
7. Ziprasidone
Posology:
Oral:
- Initial Dose: Initially, 20 mg twice daily.
- Usual Dose: Typically, the dose ranges from 40-80 mg twice daily.
- Maximum Dose: The maximum recommended dose is 160 mg twice daily.
Intramuscular:
- Initial Dose: 10-20 mg.
- Usual Dose: 10-20 mg every 2-4 hours.
- Maximum Dose: 40 mg per day.
Safety Notes: ZIP(mnemonic)-
- Drowsiness, Increased QT interval, and Prolactin increase.
8. Iloperidone
Posology:
Oral:
- Initial Dose: 1 mg twice daily.
- Usual Dose: 6-12 mg twice daily.
- Maximum Dose: 24 mg twice daily.
Safety Notes: ILOP(mnemonic)
- Increased weight, Low blood pressure, Orthostatic hypotension, and Prolactin increase.
9. Lurasidone
Posology:
- Initial Dose: 40 mg.
- Typically, the Usual Dose: ranges from 40 mg to 80 mg.
- In some cases, the Maximum Dose: is 160 mg.
Safety Notes -LURE-SIDE (mnemonic)
- Lethargy, Upset stomach, Rash, Extrapyramidal symptoms, Sedation, Increased weight, Dizziness, Elevated blood sugar.
10. Asenapine
Posology:
Sublingual Tablet:
- Initial Dose: Start with 5 mg twice daily.
- Usual Dose: The usual dose is 5–10 mg twice daily.
- Maximum Dose: The maximum recommended dose is 10 mg twice daily.
Transdermal Patch:
- Initial Dose: Begin with 5 mg/24 hours.
- Usual Dose: Typically, the dose ranges from 5–10 mg/24 hours.
- Maximum Dose: The maximum allowable dose is 10 mg/24 hours.
Safety Notes: SLEEPY-R(mnemonic)
- Sedation, Low blood pressure, Extrapyramidal symptoms, Excessive weight gain, Prolonged QT interval, Yearning and a Rash.
Conclusion
Understanding the dosing and safety profiles of different antipsychotic medications is essential since it helps guide effective treatment planning and ensures optimal patient care. Moreover, this knowledge enables healthcare providers to make informed decisions tailored to each patient’s needs. Moreover, this knowledge allows healthcare providers to tailor treatments based on individual needs, ultimately improving patient outcomes.
Comparison of Adverse Effects for Second-Generation Antipsychotics (SGAs) Antipsychotic Medications
Understanding Adverse Effects: This table, however, offers a comparative overview of common adverse effects across various SGAs. By considering these effects, you can therefore make more informed medication choices.
Medication | Sedation | Extrapyramidal Symptoms (EPS) | Anticholinergic Effects | Orthostatic Hypotension | Seizure Risk | Prolactin Increase | Potential for Weight Gain |
Clozapine | Very High | Low | Very High | Very High | High | None | Very High |
Olanzapine | High | Low | High | High | Low | None | High |
Quetiapine | High | Low | Low | Moderate | Low | None | Low |
Risperidone | Moderate | Low | Moderate | Low | Low | Low to Moderate | Low |
Aripiprazole | Moderate | Low | Low | Low | Low | None | Low |
Paliperidone | Moderate | Low | Low | Low | Low | Low to Moderate | Low |
Iloperidone | Moderate | Low | Low | Low | Low to Moderate | Low to Moderate | Low |
Asenapine | Moderate | Low | None | Low | Low to Moderate | Moderate | Moderate |
Lurasidone | Low | Low | Low to None | Low | Low to Moderate | Moderate | Low |
Notes:
- Sedation, for instance, refers to the medication’s sedative effect.
- Extrapyramidal Symptoms (EPS), on the other hand, include motor side effects such as tremors and rigidity.
- Additionally, Anticholinergic Effects encompass symptoms like dry mouth, blurred vision, and constipation.
- Meanwhile, Orthostatic Hypotension is characterized by a drop in blood pressure when standing up.
- Seizure Risk, likewise, refers to the likelihood of the medication triggering seizures.
- Furthermore, Prolactin Increase indicates whether the medication may elevate prolactin levels, potentially affecting hormone balance.
- Finally, the potential for Weight Gain underscores the likelihood of the medication causing a significant increase in body weight.
Key Points for Schizophrenia & Antipsychotics:
Actionable Tips and Resources
- Seek Professional Help: It is crucial, therefore, to consult a mental health professional for an accurate diagnosis and a personalized treatment plan.
Support Networks: Furthermore, engaging with support groups or therapy can help manage the condition and significantly improve quality of life. - Educational Resources: Explore additional resources on mental health from reputable organizations such as the National Institute of Mental Health (NIMH) and the Schizophrenia and Related Disorders Alliance of America (SARDAA).
For further reading, visit our mental health resource library or contact a professional for personalized guidance.
Mental Health Resource Library:
- National Institute of Mental Health (NIMH) Resource Library: NIMH Resource Library
- American Psychological Association (APA) Topics: APA Mental Health Topics
- Mental Health America (MHA) Resources: MHA Mental Health Library
Find a Mental Health Professional:
- American Psychiatric Association (APA) Find a Psychiatrist: Find a Psychiatrist
Glossary
- Dopamine: This neurotransmitter plays a crucial role in mood regulation as well as reward pathways.
- Glutamate: In addition, glutamate is an excitatory neurotransmitter that is crucial for cognitive functions.
- Serotonin: Furthermore, serotonin influences mood, anxiety, and sleep, making it essential for emotional balance.
- GABA: Finally, GABA is an inhibitory neurotransmitter that helps regulate neuronal excitability; as a result, it promotes overall brain stability.
Treatment-resistant schizophrenia (TRS):
Treatment-resistant schizophrenia (TRS) is defined as a lack of adequate response to at least two different antipsychotic medications prescribed at therapeutic doses for a sufficient duration, typically 6–8 weeks each. It also requires persistent symptoms despite adherence to treatment and the exclusion of other factors that could affect treatment response. Recent studies indicate that Clozapine is the preferred antipsychotic for TRS due to its superior effectiveness.
Factor | Recommendations |
For Weight Concerns | – Preferred: Aripiprazole, Lurasidone – Avoid: Olanzapine, Quetiapine |
For Sedation Issues | – Preferred: Aripiprazole, Ziprasidone – Avoid: Quetiapine, Olanzapine |
For High Risk of Extrapyramidal Symptoms | – Preferred: Quetiapine, Clozapine – Avoid: Risperidone, Aripiprazole |
For Treatment-Resistant Schizophrenia | – Preferred: Clozapine – Other Options: Aripiprazole, Olanzapine |
For Bipolar Disorder with Mixed Symptoms | – Preferred: Quetiapine, Olanzapine – Other Options: Aripiprazole |
References:
- Muench, J., & Hamer, A. M. (2010). Adverse effects of antipsychotic medications. American Family Physician, 81(5), 617-622.
- Muller, M. J., & Muehlbacher, M. (2017). Management of schizophrenia: A review. World Journal of Psychiatry, 7(2), 105-113. https://doi.org/10.5498/wjp.v7.i2.105
- Lehman, A. F., & Steinwachs, D. M. (1998). Assessing the quality of life in people with severe mental illness. Schizophrenia Bulletin, 24(1), 39-50. https://doi.org/10.1093/schbul/24.1.39
- Kane, J. M., & Correll, C. U. (2010). Pharmacologic treatment of schizophrenia. Dialogues in Clinical Neuroscience, 12(3), 345-357. https://doi.org/10.31887/DCNS.2010.12.3/jkane
- National Institute for Health and Care Excellence (NICE). (2014). Psychosis and schizophrenia in adults: Treatment and management (Clinical guideline CG178). Retrieved from https://www.nice.org.uk/guidance/cg178
- Drugs.com
- Micromedex
- NICE Guidelines: https://cks.nice.org.uk/topics/obsessive-compulsive-disorder/prescribing-information/ssris/
**Disclaimer**: The information in this article is intended for informational purposes only and, therefore, should not be considered medical advice. Instead, always consult a healthcare professional for an accurate diagnosis and appropriate treatment of medical conditions.
1 comment so far